Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data

Hans Christoph Diener, Julien Bogousslavsky, Lawrence M. Brass, Claudio Cimminiello, L. Csiba, Markku Kaste, Didier Leys, Jordi Matias-Guiu, Hans Jürgen Rupprecht

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease. The benefit of clopidogrel over ASA is amplified in high-risk patients. Proof of concept for the benefit of clopidogrel in addition to ASA in patients with coronary manifestations of atherothrombosis was provided by the CURE trial. Methods: MATCH is a randomized, double-blind, placebo-controlled trial that compares clopidogrel and ASA versus clopidogrel alone in high-risk patients with recently symptomatic cerebrovascular disease. Eligible patients have experienced a transient ischaemic attack (TIA) or IS within the last 3 months and have evidence of at least 1 additional risk factor within the last 3 years (prior IS, MI, stable or unstable angina pectoris, diabetes or symptomatic peripheral arterial disease). Patients were randomized to receive ASA 75 mg once daily or placebo, with both groups receiving clopidogrel 75 mg once daily as part of standard therapy. The primary end point is the composite of IS, MI, vascular death and rehospitalization for an acute ischaemic event. The duration of treatment and follow-up is 18 months for each patient. Results: Enrolment was completed in April 2002, with 7,599 patients randomized to receive the study medication. The mean age at randomization was 66 years, and the qualifying event was IS in 78.9% of patients and TIA in 21.1%. The baseline features of the study cohort indicate a population that is at a high risk for atherothrombotic recurrence. Conclusion: MATCH is a major ongoing trial that will provide important data on the benefit of clopidogrel and ASA compared with clopidogrel alone for reduction of vascular ischaemic events in patients with recent TIA or IS who are at high risk of atherothrombotic event recurrence.

Original languageEnglish
Pages (from-to)253-261
Number of pages9
JournalCerebrovascular Diseases
Volume17
Issue number2-3
DOIs
Publication statusPublished - 2004

Fingerprint

clopidogrel
Transient Ischemic Attack
Stroke
Aspirin
Peripheral Arterial Disease
Myocardial Infarction
Blood Vessels
Placebos
Cerebrovascular Disorders
Recurrence
Stable Angina

Keywords

  • Acetylsalicylic acid
  • Antiplatelet therapy
  • Atherothrombosis
  • Clopidogrel
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH) : Study design and baseline data. / Diener, Hans Christoph; Bogousslavsky, Julien; Brass, Lawrence M.; Cimminiello, Claudio; Csiba, L.; Kaste, Markku; Leys, Didier; Matias-Guiu, Jordi; Rupprecht, Hans Jürgen.

In: Cerebrovascular Diseases, Vol. 17, No. 2-3, 2004, p. 253-261.

Research output: Contribution to journalArticle

Diener, Hans Christoph ; Bogousslavsky, Julien ; Brass, Lawrence M. ; Cimminiello, Claudio ; Csiba, L. ; Kaste, Markku ; Leys, Didier ; Matias-Guiu, Jordi ; Rupprecht, Hans Jürgen. / Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH) : Study design and baseline data. In: Cerebrovascular Diseases. 2004 ; Vol. 17, No. 2-3. pp. 253-261.
@article{e346e3bde7c74c2aad61c2bf5e0e2b1a,
title = "Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data",
abstract = "Background: The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease. The benefit of clopidogrel over ASA is amplified in high-risk patients. Proof of concept for the benefit of clopidogrel in addition to ASA in patients with coronary manifestations of atherothrombosis was provided by the CURE trial. Methods: MATCH is a randomized, double-blind, placebo-controlled trial that compares clopidogrel and ASA versus clopidogrel alone in high-risk patients with recently symptomatic cerebrovascular disease. Eligible patients have experienced a transient ischaemic attack (TIA) or IS within the last 3 months and have evidence of at least 1 additional risk factor within the last 3 years (prior IS, MI, stable or unstable angina pectoris, diabetes or symptomatic peripheral arterial disease). Patients were randomized to receive ASA 75 mg once daily or placebo, with both groups receiving clopidogrel 75 mg once daily as part of standard therapy. The primary end point is the composite of IS, MI, vascular death and rehospitalization for an acute ischaemic event. The duration of treatment and follow-up is 18 months for each patient. Results: Enrolment was completed in April 2002, with 7,599 patients randomized to receive the study medication. The mean age at randomization was 66 years, and the qualifying event was IS in 78.9{\%} of patients and TIA in 21.1{\%}. The baseline features of the study cohort indicate a population that is at a high risk for atherothrombotic recurrence. Conclusion: MATCH is a major ongoing trial that will provide important data on the benefit of clopidogrel and ASA compared with clopidogrel alone for reduction of vascular ischaemic events in patients with recent TIA or IS who are at high risk of atherothrombotic event recurrence.",
keywords = "Acetylsalicylic acid, Antiplatelet therapy, Atherothrombosis, Clopidogrel, Stroke",
author = "Diener, {Hans Christoph} and Julien Bogousslavsky and Brass, {Lawrence M.} and Claudio Cimminiello and L. Csiba and Markku Kaste and Didier Leys and Jordi Matias-Guiu and Rupprecht, {Hans J{\"u}rgen}",
year = "2004",
doi = "10.1159/000076962",
language = "English",
volume = "17",
pages = "253--261",
journal = "Cerebrovascular Diseases",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "2-3",

}

TY - JOUR

T1 - Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH)

T2 - Study design and baseline data

AU - Diener, Hans Christoph

AU - Bogousslavsky, Julien

AU - Brass, Lawrence M.

AU - Cimminiello, Claudio

AU - Csiba, L.

AU - Kaste, Markku

AU - Leys, Didier

AU - Matias-Guiu, Jordi

AU - Rupprecht, Hans Jürgen

PY - 2004

Y1 - 2004

N2 - Background: The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease. The benefit of clopidogrel over ASA is amplified in high-risk patients. Proof of concept for the benefit of clopidogrel in addition to ASA in patients with coronary manifestations of atherothrombosis was provided by the CURE trial. Methods: MATCH is a randomized, double-blind, placebo-controlled trial that compares clopidogrel and ASA versus clopidogrel alone in high-risk patients with recently symptomatic cerebrovascular disease. Eligible patients have experienced a transient ischaemic attack (TIA) or IS within the last 3 months and have evidence of at least 1 additional risk factor within the last 3 years (prior IS, MI, stable or unstable angina pectoris, diabetes or symptomatic peripheral arterial disease). Patients were randomized to receive ASA 75 mg once daily or placebo, with both groups receiving clopidogrel 75 mg once daily as part of standard therapy. The primary end point is the composite of IS, MI, vascular death and rehospitalization for an acute ischaemic event. The duration of treatment and follow-up is 18 months for each patient. Results: Enrolment was completed in April 2002, with 7,599 patients randomized to receive the study medication. The mean age at randomization was 66 years, and the qualifying event was IS in 78.9% of patients and TIA in 21.1%. The baseline features of the study cohort indicate a population that is at a high risk for atherothrombotic recurrence. Conclusion: MATCH is a major ongoing trial that will provide important data on the benefit of clopidogrel and ASA compared with clopidogrel alone for reduction of vascular ischaemic events in patients with recent TIA or IS who are at high risk of atherothrombotic event recurrence.

AB - Background: The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease. The benefit of clopidogrel over ASA is amplified in high-risk patients. Proof of concept for the benefit of clopidogrel in addition to ASA in patients with coronary manifestations of atherothrombosis was provided by the CURE trial. Methods: MATCH is a randomized, double-blind, placebo-controlled trial that compares clopidogrel and ASA versus clopidogrel alone in high-risk patients with recently symptomatic cerebrovascular disease. Eligible patients have experienced a transient ischaemic attack (TIA) or IS within the last 3 months and have evidence of at least 1 additional risk factor within the last 3 years (prior IS, MI, stable or unstable angina pectoris, diabetes or symptomatic peripheral arterial disease). Patients were randomized to receive ASA 75 mg once daily or placebo, with both groups receiving clopidogrel 75 mg once daily as part of standard therapy. The primary end point is the composite of IS, MI, vascular death and rehospitalization for an acute ischaemic event. The duration of treatment and follow-up is 18 months for each patient. Results: Enrolment was completed in April 2002, with 7,599 patients randomized to receive the study medication. The mean age at randomization was 66 years, and the qualifying event was IS in 78.9% of patients and TIA in 21.1%. The baseline features of the study cohort indicate a population that is at a high risk for atherothrombotic recurrence. Conclusion: MATCH is a major ongoing trial that will provide important data on the benefit of clopidogrel and ASA compared with clopidogrel alone for reduction of vascular ischaemic events in patients with recent TIA or IS who are at high risk of atherothrombotic event recurrence.

KW - Acetylsalicylic acid

KW - Antiplatelet therapy

KW - Atherothrombosis

KW - Clopidogrel

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=1942531422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942531422&partnerID=8YFLogxK

U2 - 10.1159/000076962

DO - 10.1159/000076962

M3 - Article

C2 - 14981346

AN - SCOPUS:1942531422

VL - 17

SP - 253

EP - 261

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 2-3

ER -